NASDAQ NMS - GLOBAL MARKET · KYTX
+0.97% · +$0.0600 · Vol 483.0K
Live · updated 15:15:46 ET
Kyverna Therapeutics Inc

Kyverna Therapeutics Inc

Biotechnology
$6.22
Card
Relationship Map

Follow $KYTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KYTX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
KYTX
Kyverna Therapeutics Inc
Wed Oct 7 · live session · daily score · 2h old
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

57/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · live session · daily score · 2h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KYTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KYTX catalysts
About Kyverna Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2024
Employees
149
Country
US

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.12
Day high
$6.31
Day low
$6.02
Previous close
$6.16
52W high
$11.25
-44.71% from high
52W low
$5.41
14% of range
Market cap
$381M
EPS
$-2.9350
Beta
1.49
Shares out
61.8M
Volume
483K
0.55× rel vol
Avg volume
881K
VWAP
$6.22
Price history computed in-house
1W
-8.53%
1M
-24.61%
3M
-36.60%
1Y
+14.97%
YTD
-33.83%
SMA 50 $7.65 · below
SMA 200 $8.33 · below
52W position 14%

KYTX overview

Veridion Score
57
Registered · 2026-10-06
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KYTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KYTX Form 4 filings
Public disclosures

Congress activity in KYTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

KYTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KYTX in this window.
Lobbying spend

KYTX lobbying filings, year to date.

Registered lobbying filings matched to Kyverna Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KYTX in this window.
Loading news for KYTX
Analyst ratings
Sovereign unlock shows live analyst consensus for KYTX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.